WallStreetZenWallStreetZen

NASDAQ: ALNY
Alnylam Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Alnylam Pharmaceuticals earnings were $808.0M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest ALNY earnings report on Jun 30, 2026 announced Q2 2026 earnings of $164.5M, down 20.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ALNY reported annual earnings of $313.7M, with -212.8% growth.

ALNY earnings history

Current Revenue
$4.8B
Current Earnings
$808.0M
Current Profit Margin
16.8%

ALNY Return on Equity

Current Company
93.6%
Current Industry
-13.6%
Current Market
28.9%
ALNY's Return on Equity (93.6%)... subscribe to Premium to read more.
High Return on Equity Performance

ALNY Return on Assets

Current Company
15.8%
Current Industry
-10.2%
ALNY is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when ALNY announces earnings.

ALNY Return on Capital Employed

Current Company
27.79%
Current Industry
-6.7%
ALNY has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ALNY vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
ALNY$1.18B$807.99MN/A$6.10
BNTX-$1.03B-$1.92BN/A-$7.63
RPRX$1.18B$815.00M-5.47%$1.88
INSM-$758.47M-$875.31MN/A-$4.10
ROIV-$130.95M-$266.25MN/A-$0.36
View Top Biotech Stocks

Alnylam Pharmaceuticals Earnings Reports & History FAQ

What were Alnylam Pharmaceuticals's earnings last quarter?

On ALNY's earnings call on Jul 30, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q2 2026 earnings per share (EPS) of $1.23, up 323.64% year over year. Total ALNY earnings for the quarter were $164.49 million. In the same quarter last year, Alnylam Pharmaceuticals's earnings per share (EPS) was -$0.55.

If you're new to stock investing, here's how to buy Alnylam Pharmaceuticals stock.

Is Alnylam Pharmaceuticals profitable or losing money?

As of the last Alnylam Pharmaceuticals earnings report, Alnylam Pharmaceuticals is currently profitable. Alnylam Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $807.99 million, a 382.7% decrease year over year.

What was ALNY's earnings growth in the past year?

As of Alnylam Pharmaceuticals's earnings date in Jul 30, 2026, Alnylam Pharmaceuticals's earnings has grown year over year. ALNY earnings in the past year totalled $807.99 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.